M Men, the antimuscarinics. Antimuscarinic Lenalidomide Revlimid dose not seem to affect the risk of AUR. Clinicians findings nnten k Systematically arrange LUTS at M Nnern with BOO from BPO and prescribe treatments directed to the prostate. However, k Can see M Men symptom My OAB or DO in the absence of symptoms for invalid explained Ren and BOO, and many men remain symptom My OAB or DO, in spite of treatment, the mag AREA of the prostate. The results of the randomized, double-blind, time Adam and Victor MacDiarmid et al. Studies provide compelling evidence that antimuscarinic blocker therapy significant advantage for M Men Including with LUTS Lich symptoms of overactive bladder, and has several prospective studies have also shown that antimuscarinic blocker is effective for the symptoms of OAB only a blocker of M . nnern These results are consistent with a meta-analysis of data from five randomized trials and 15 observational studies, the M nnern With LUTS of BPO, with antimuscarinic improved IPSS scores, scores especially in storage, was found and included in general a positive effect on HRQOL. These results are important because the symptom My storage that define OAB h Frequently in M Found nnern and influence HRQOL, perhaps in a green Eren Ausma as urinary symptoms. Most evidence nnern that antimuscarinics alone can effectively treat the symptoms of overactive bladder with M. However, tolterodine ER alone was not a very effective tool in the Bev Lkerung the study period, probably due to the study population, only TIME. The severity of LUTS in M Nnern h times in the study Ago as in other studies of LUTS in nnern M, IPSS base ranges from 19.5 to 20.6 between treatment groups in the study, 16.8 vs. 17.6 hours among the treatment groups in the medical therapy of prostatic symptoms study. In addition, subjects were TIMES meet entry criteria for both overactive bladder and test outsourcing. So many M Men had LUTS probably resulting from both the bladder and prostate related pathology in the context, and some may have had a symptom My secondary Ren memory with prostate pathology associated t satisfied, that the primitive relatives bladder pathology were tested stricter than in most populations. A nachtr Possible analysis of the data revealed that the tolterodine ER effectively in times of M Nnern with prostate size E or PSA was below the median of the study. So happened, the available data alone antimuscarinic ad To relieve LUTS quat at M Nnern symptoms of overactive bladder due to primitive conditions of the bladder with symptoms of little or no discharge. Antimuscarinics is more of a reductase inhibitor or blocking 5a may be necessary for adequate reduction of M Men with LUTS and BPO achieve symptoms of overactive bladder as a result of concomitant disease of the bladder or secondary Re. The Gr E of the prostate or the PSA level may develop guidelines for the treatment strategy that will benefit the most from them give the individual, although the treatment must be adapted as a rule, to maximize the effectiveness in individual patients. The studies reviewed here also point out that regarding the prescribing of anti-muscarinic M Men with symptoms of storage on the perception that these drugs verst Strengths or executed Filled AUR PVR, because the mechanism of action may be necessary, a reassessment is based. The Times and ADAM studies, Ver Changes in Qmax and PVR not ClinicAll.